摘要
目的观察益肾清利和络泄浊综合疗法长期治疗对慢性肾脏病(Chronic kidney disease,CKD)4期患者的有效性及安全性。方法以2015年1月至2019年6月在江苏省中医院肾内科接受益肾清利和络泄浊中药治疗并纳入门诊慢病管理系统的共339例CKD 4患者为研究对象,以估算肾小球滤过率(Estimated glomerular filtration rate,eGFR)为主要观察指标、进入CKD 5期为终点事件,每3个月为1疗程,回顾性与前瞻性相结合分析临床资料。结果我们观察分析了经益肾清利和络泄浊法干预的339例CKD 4期患者的临床资料。eGFR在益肾清利和络泄浊治疗的前3个月显著升高,而在随后的9个月中eGFR缓慢稳定的增加。在治疗3个月时,患者Scr水平较基线下降,6、9、12个月时Scr较基线水平上升,总体保持稳定。对血红蛋白、白蛋白、24 h尿蛋白定量无明显影响。在观察期内,患者WBC、AST,ALT,K皆无显著变化,且无严重不良反应发生。结论经益肾清利和络泄浊综合疗法干预的CKD 4期患者在1年内的eGFR保持稳定,未见明显不良反应。
Objective To observe the efficacy and safety of long-term Chinese medicine treatment of"Yishen Qingli Heluo Xiezhuo"on renal function in patients with stage 4 chronic kidney disease(CKD).Methods 339 patients with stage 4 CKD who received Chinese herbal medicine of"Yishen Qingli Heluo Xiezhuo"from January 2015 to July 2019 in nephrology division of Jiangsu Province Hospital of Chinese Medicine and included in the Outpatient Chronic Disease Management System were enrolled as research subjects.The estimated glomerular filtration rate(eGFR)was taken as primary observation index,and progression of CKD stage 4 to stage 5 as end-points event.Every three months was taken as one treatment course.The clinical data were analyzed retrospectively and prospectively.Results We observed and analyzed the data of 339 patients with stage 4 CKD receiving comprehensive treatment with"Yishen Qingli Heluo Xiezhuo".The eGFR increased significantly in the first 3 months after the treatment of"Yishen Qingli Heluo Xiezhuo and steadily in the following 9 months.At 3 months of treatment,the Scr of patients decreased from baseline,while at 6,9 and 12 months,Scr increased from baseline and remained stable overall.There was no significant effect on hemoglobin,albumin and 24-hour urinary protein.During the observation period,there were no significant changes in WBC,AST,ALT and K,and no serious adverse reactions occurred.Conclusion The eGFR of stage 4 CKD patients treated with the combined therapy of"Yishen Qingli Heluo Xiezhuo"remained stable within one year,and no obvious adverse reactions were observed.
作者
高坤
赵静
易岚
郑敏
严谨
刘利华
陈继红
张露
孙伟
Gao Kun;Zhao Jing;Yi Lan;Zheng Min;Yan Jin;Liu Lihua;Chen Jihong;Zhang Lu;Sun Wei(Jiangsu Province Hospital of Chinese Medicine,The Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2021年第10期3462-3467,共6页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
国家中医药管理局重大疑难病中西医临床协作试点项目(国中医药办医政发【2018】3号):慢性肾功能衰竭,负责人:孙伟
国家中医药管理局2015年度国家中医临床研究基地业务建设第二批科研专项(JDZX2015092):基于“真实世界”原理评价益肾清利活血泄浊法治疗慢性肾脏病(CKD 4期)的临床有效性及安全性研究,负责人:高坤。
关键词
慢性肾脏病4期
中医药治疗
临床研究
益肾清利和络泄浊法
Stage 4 chronic kidney disease
Chinese medicine therapy
Clinical study
Yishen Qingli Heluo Xiezhuo
